Mathematical modeling of routine biological parameters kinetics in order to predict durable benefit for first-line immunotherapy in metastatic or unresectable melanoma

被引：0
|
作者：
Forestier, Jessica
Daumas, Alice Julie
Richard, Marie-Aleth
Gaudy-Marqueste, Caroline
Benzekry, Sebastien
Malissen, Nausicaa
机构：
[1] Aix Marseille Univ, CHU Timone, APHM, Dermatol & Skin Canc Dept,CRCM Inserm U1068,CNRS, Marseille, France
[2] Aix Marseille Univ, COMPutat Pharmacol & Clin Oncol, Ctr Inria Univ Cote Azur,Inst Paoli Calmettes, Ctr Rech Cancerol Marseille,Inserm U1068,CNRS U72, Marseille, France
[3] Aix Marseille Univ, Assistance Publ Hop Marseille, Dermatol & Skin Canc Dept, CEPCM, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21549
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-world treatment patterns and outcomes among patients with BRAF plus metastatic melanoma refractory to first-line immunotherapy
    Truong, T. G.
    Chandra, S.
    Connolly, L.
    Shah, R.
    Byrne, C.
    Tang, J.
    Eroglu, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S673 - S673
  • [22] Immunotherapy or targeted therapy as first-line treatment of patients with advanced/metastatic melanoma with the BRAF mutation - a single-center analysis
    Cybulska-Stopa, Bozena
    Piejko, Karolina
    Pacholczak, Renata
    Domagala-Haduch, Malgorzata
    Drosik-Kwasniewska, Anna
    Satek-Zan, Agata
    Wiktor-Mucha, Patrycja
    Rolski, Janusz
    Zemetka, Tomasz
    ONCOLOGY IN CLINICAL PRACTICE, 2020, 16 (04): : 194 - 200
  • [23] NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma
    Flaherty, Keith
    Arenberger, Petr
    Ascierto, Paolo Antonio
    De Groot, Jan Willem
    Hallmeyer, Sigrun
    Long, Georgina V.
    Lotem, Michel
    Marples, Maria
    Schadendorl, Dirk
    Starodub, Alexander
    Taylor, Matthew Hiram
    Wolter, Pascal
    Yamazaki, Naoya
    Wasserman, Ernesto
    Ford, James
    Weill, Marine
    Dummer, Reinhard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
    Delea, Thomas E.
    Amdahl, Jordan
    Wang, Alice
    Amonkar, Mayur M.
    Thabane, Marroon
    PHARMACOECONOMICS, 2015, 33 (04) : 367 - 380
  • [25] Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
    Thomas E. Delea
    Jordan Amdahl
    Alice Wang
    Mayur M. Amonkar
    Marroon Thabane
    PharmacoEconomics, 2015, 33 : 367 - 380
  • [26] Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study
    Chatziioannou, E.
    Higuita, L. M. Serna
    Kreft, S.
    Kandolf, L.
    Dujovic, B.
    Reinhardt, L.
    Tamara, E.
    Marquez-Rodas, I.
    Fortuna, A. R. F. P.
    Nubling, A.
    Niessner, H.
    Forschner, A.
    Garbe, C.
    Popovic, A.
    Mirjana, B.
    Meier, F.
    Eigentler, T.
    Leiter, U.
    Flatz, L.
    Sinnberg, T.
    Amaral, T.
    ESMO OPEN, 2024, 9 (08)
  • [27] Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer
    Yin, Chenxi
    Jiang, Chang
    Liao, Fangxin
    Rong, Yuming
    Cai, Xiuyu
    Guo, Guifang
    Qiu, Huijuan
    Chen, Xuxian
    Zhang, Bei
    He, Wenzhuo
    Xia, Liangping
    ONCOTARGETS AND THERAPY, 2014, 7 : 1415 - 1422
  • [28] Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial
    Salfati, Delphine
    Huot, Margaux
    Aparicio, Thomas
    Lepage, Come
    Taieb, Julien
    Bouche, Olivier
    Boige, Valerie
    Phelip, Jean-Marc
    Dahan, Laetitia
    Bennouna, Jaafar
    Le Malicot, Karine
    Boussari, Olayide
    Gornet, Jean-Marc
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (06) : 791 - 798
  • [29] A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy
    Nicolini, Andrea
    Rossi, Giuseppe
    Ferrari, Paola
    Morganti, Riccardo
    Carpi, Angelo
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2020, 98 (03): : 375 - 382
  • [30] A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy
    Andrea Nicolini
    Giuseppe Rossi
    Paola Ferrari
    Riccardo Morganti
    Angelo Carpi
    Journal of Molecular Medicine, 2020, 98 : 375 - 382
12345